

Publications

Markus Hansson, M.D., Ph.D.

Citations: >1600, h-index: 20, i10-index: 32
Total no published original research papers: 42
Total no published reviews/book chapter: 11
Total no published abstracts: 32
Total no patents: 2
Total no published popular science papers/presentations: 6
Total no submitted papers: 4

I. Original research papers

1. Wichert S, Juliusson G, Johansson A, Sonesson E, Teige I, Wickenberg AT, Frendeus B, Korsgren M, **Hansson M**. A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response following Treatment with BI-505, a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients with Smoldering Multiple Myeloma (2017) **PLoS ONE** 12(2): e0171205
2. Halvarsson BM, Wihlborg AK, Ali M, Lemonakis K, Johnsson E, Niroula A, Sougnez C, Mellqvist UH, Turesson I, Waage A, Hemminki K, Nahi H, Golub T, Gullberg U, **Hansson M***, Nilsson B*. Direct evidence for a polygenic etiology in familial multiple myeloma (2017) **Blood Adv** 1(10) 619-623 (**shared coordinating author*)
3. Went M, Sud A, Law P, Johnson D, Weinhold N, Frsti A, van Duin M, Mitchell J, Chen B, Kuiper R, Stephens O, Bertsch U, Campo C, Einsele H, Gregory W, Henrion M, Hillengass J, Hoffmann P, Jackson G, Lenive O, Nickel J, Nothen M, da Silva Filho M, Thomsen H, Walker B, Broyl A, Davies F, Langer C, **Hansson M**, Kaiser M, Sonneveld P, Goldschmidt H, Hemminki K, Nilsson B, Morgan G, Houlston R. Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach (2017) **Blood Cancer J** *accepted*
4. Dimopoulos M, Richardson P, Siegel D, Cavo M, Corradini P, Weisel K, Delforge M, O’Gorman P, Song K, Chen C, Bahlis N, Oriol A, **Hansson M**, Kaiser M, Anttila P, Raymakers R, Joao C, Cook G, Sternas L, Biyukov T, Slaughter A, Hong K, Herring J, Yu X, Zaki M, San-Miguel J, Moreau P. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: a pooled analysis from three clinical trials. (2017) **Eur J Haematol** *accepted*
5. Kumar S, Dimopoulos M, Kastiris E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio E, Mateos M, O’Donnell E, Vij R, Lokhorst H, van de Donk N, Min CK, Mark T, Turesson I, **Hansson M**, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist UH, Usmani S, Dytfeld D, Badros A, Moreau P, Kim K, Rodriguez Otero P, Lee J, Shustik C, Waller D, Chang W, Ozaki S, Lee JJ, de la Rubia J, Eom H, Rosinol L, Lahuerta J, Sureda A, Kim J, Durie D. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study (2017) **Leukemia** *accepted*
6. Aurelius J, Hallner A, Werlenius O, Riise R, Möllgård L, Brune M, **Hansson M**, Martner A, Thoren F, Hellstrand K. NOX2-dependent immunosuppression in chronic myelomonocytic leukemia (2017) **J Leukoc Biol** *accepted*
7. Moreau P, Masszi T, Grzasko N, Bahlis NJ, **Hansson M**, Pour L, Sandhu I, Ganly P, Baker BW, Jackson S, Stoppa AM, Simpson D, Gimsing P, Palumbo A, Cavo M, Kumar S, Berg DT, Lin J, Hui AH and Richardson P on behalf of the TOURMALINE-MM1 study group. Oral Ixazomib, Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma (2016) **N Engl J Med** 374(17):1621-1634.

8. Wichert S, Pettersson Å, Hellmark T, Johansson Å*, **Hansson, M***. The Phagocyte Function is Decreased post High-Dose Treatment with Melphalan and Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (2016) **Exp Hematol** 44(5):342-351 (**shared coordinating author*)
9. Zweegman S., Holt van der B, Mellqvist UH, Salomo M, Bos GMJ, Levin MD, Visser-Wisselaar H, **Hansson M**, van der Velden AWD, Deenik W, Gruber A, Coenen JLLM, Plesner T, Klein SK, Tanis BC, Szatkowski D, Brouwer RE, Westerman M, Leys MBL, Sinnige HAM, Haukas E, van der Hem KG, Durian MF, Mattijssen EJM, van de Donk NWCJ, Stevens-Kroef MJPL, Sonneveld P, Waage A. Melphalan, Prednisone and Lenalidomide versus Melphalan, Prednisone and Thalidomide; the HOVON 87/NMSG18 phase 3 trial (2016) **Blood** 127(9):1109-16.
10. Johansson A, Olsson S, Pettersson A, Bengtsson A, Selga D, **Hansson M**, Hellmark T. Impaired phagocytosis and reactive oxygen species production in phagocytes is associated with systemic vasculitis. (2016) **Arthritis Research and Therapy** 18:92
11. Mitchell JS, Li N, Weinhold N, Frsti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen B, Halvarsson BM, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Einsele H, Gregory WA, Gullberg G, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Johnsson E, Jöud M, Kristinsson SY, Lenhoff S, Lenive O, Mellqvist UH, Migliorini G, Nahi H, Nelander S, Nickel J, Nthen MM, Rafnar T, Ross FN, Filho M, Swaminathan B, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, Wihlborg AK, Broijl A, Davies FE, Thorsteinsdottir U, Langer C, **Hansson M**, Kaiser M, Sonneveld S, Stefansson K, Morgan G, Goldschmidt H, Hemminki K, Nilsson B, Houlston R. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. (2016) **Nature communications** 7:12050
12. Dimopoulos M, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel K, Oriol A, **Hansson M**, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San Miguel J, de Arriba F, Knop S, Rllig C, Ocio E, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki M, Moreau P. Safety and Efficacy of Pomalidomide plus low-dose dexamethasone in the STRATUS (MM-010): a phase 3b study in refractory multiple myeloma (2016) **Blood** 128(4):497-503
13. Lokhorst H, Plesner T, Laubach J, Nahi H, Gimsing P, **Hansson M**, Minnema M, Lassen U, Krejcik J, Palumbo A, van de Donk N, Ahmadi T, Khan I, Uhlar C, Wang J, Sasser K, Losic N, Lisby S, Basse L, Brun N and Richardson P. Targeting CD38 With Daratumumab Monotherapy in Multiple Myeloma (2015) **N Engl J Med** 373(13):1207-19
14. **Hansson M**, Gimsing P, Badros A, Niskanen TM, Nahi H, Offner F, Salomo M, Sonesson E, Mausorenson M, Stenberg Y, Sundberg A, Teige I, Van Droogenbroeck J, Wichert S, Zangari M, Frendeus B, Korsgren M, Poelman M and Tricot G. A phase 1, multicenter, open-label, dose escalation study of BI-505, an ICAM-1 antibody, in patients with advanced multiple myeloma. (2015) **Clinical Cancer Research** 21(12):2730-6
15. Swaminathan B, Jöud M, Ali M, Thorleifsson G, Halvarsson BM, Johnsson E, Ajore R, Hultman C, Ingelsson E, Christophersen MK, Lenhoff S, Mellqvist UH, Nahi H, Nelander S, Vangstedt A, Vogel U, Waage A, Turesson I, Gullberg U, Stefansson K*, **Hansson M***, Thorsteinsdottir U*, Nilsson B.* Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. (2015) **Nature communications** 6:7213 (**shared coordinating author*)
16. Roghanian A, Teige I, Mårtensson L, Cox KL, Kovacek M, Ljungars A, Mattson J, Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan HT, Li ZC, Williams EL, Manfredi G, Oldham RJ, Mockridge CI, James SA, Dahal LN, Hussain K, Nilsson B, Verbeek JS, Juliusson G, **Hansson M**, Jerkeman M, Johnson PW, Davies A, Beers SA, Glennie MJ, Frendeus B, Cragg MS. Antagonistic FcRIIB antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. (2015) **Cancer Cell** 27(4):473-88

17. Safavi S, **Hansson M**, Karlsson K, Biloglav A, Johansson B, Paulsson K. Novel gene targets detected by genomic profiling in a consecutive series of 126 adult acute lymphoblastic leukemia cases. (2015) **Haematologica** 100(1):55-61
18. Moreau P, Masszi T, Grzasko N, Bahlis NJ, **Hansson M**, Pour L, Sandhu I, Ganly P, Baker BW, Jackson S, Stoppa AM, Simpson D, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach J, Di Bacco A, Lin J, Berg D, Hui AM, Richardson P. Congress paper: Ixazomib, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone, Significantly Extends Progression-Free Survival for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 TOURMALINE-MM1 Study (2015) **Blood** 126(23):727
19. Borg S, Nahi H, **Hansson M**, Lee D, Elvidge J, Persson U. Cost-effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden (2015) **Acta Oncologica** 1-7
20. Safavi S, Olsson L, Biloglav A, Veerla S, Blendberg M, Tayebwa J, Behrendtz M, Castor A, **Hansson M**, Johansson B, Paulsson K. Genetic and epigenetic characterization of hypodiploid acute lymphoblastic leukemia (2015) **Oncotarget** 6(40):42793-802
21. Frigesi I, Adolfsson J, Johansson E, Kronborg-Christophersen M, Turesson I, Gullberg U, **Hansson M***, Nilsson B*. Robust cell surface markers for isolating bone marrow plasma cells in multiple myeloma. (**shared coordinating author*) (2014) **Blood** 123(9):1336-40
22. Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan GJ, Davies FE, Sonneveld P, Schey SA, Zweegman S, **Hansson M**, Weisel K, Mateos MV, Facon T, San Miguel SF. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. (2014) **Leukemia** 28(8):1573-85
23. Bengtsson A, Pettersson Å, Wichert S, Gullstrand B, **Hansson M**, Hellmark T, Johansson Å. Low production of reactive oxygen species in granulocytes is associated with organ damage in Systemic Lupus Erythematosus. (2014) **Arthritis Research Therapy** 16(3):R120
24. Veitonmäki N*, **Hansson M***, Zhan F, Sundberg A, Löfstedt T, Ljungars A, Li ZH, Martinsson-Niskanen T, Zeng M, Yang Y, Danielsson L, Kovacek M, Lundqvist A, Mårtensson L, Teige I, Tricot G, Frendeus B. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent anti-myeloma activity in vivo. (2013) **Cancer Cell** 23(4):502-15. (**shared first author*)
25. Aurelius J, Bergh-Thoren F, Akhiani A, Brune M, Palmqvist L, **Hansson M**, Hellstrand K, Martner A. Monocytic AML cells inactivate anti-leukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis. (2012) **Blood** 119(24):5832-7.
26. Aurelius J, Martner A, Brune M, Palmqvist L, **Hansson M**, Hellstrand K, Bergh-Thoren F. Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells. (2012) **Haematologica** 97(12):1904-8
27. Källquist, L, Rosen H, Nordenfelt P, Calafat J, Janssen H, Persson AM, **Hansson M***, Olsson, I*. Neutrophil elastase and proteinase 3 trafficking routes in myelomonocytic cells. (2010) **Exp Cell Res.** 316(19):3182-96. (**(shared last authorship)*)
28. Johansson Å, Nandakumar KS, Persson AM, Olsson I, **Hansson M**. Targeting of soluble TNF-receptor into secretory lysosomes of murine hematopoietic cells as a principle for in vivo immunoregulation in inflammation and malignancy. (2009) **Exp Hematol** 37(8):969-78.
29. Källqvist L, **Hansson M**, Persson AM, Janssen H, Calafat J, Tapper H, Olsson I. The tetraspanin CD63 interacts with neutrophil proelastase and is required for secretory lysosome formation in granulopoietic cells. (2008) **Blood** 112(8):3444-54.
30. **Hansson M**, Jerkeman M, Dictor M. Biphenotypic bigenotypic lymphoma with simultaneous expression of PAX5/BSAP and B and T-cell markers. (2007) **Eur J Hematol** 79(2):159-65.

31. Tapper H, Källqvist L, Johnsson E, Persson AM, **Hansson M**, Olsson I. Neutrophil elastase sorting involves plasma membrane trafficking requiring the C-terminal propeptide. (2006) **Exp Cell Res** 1;312(18):3471-84.
32. Gao Y, Tapper H, Calafat J, Olsson I, **Hansson M**. Granule targeting of soluble tumor necrosis factor (TNF) receptor expressed during granulopoietic maturation in murine bone marrow cells. (2006) **Eur Cytokine Netw** 17:98-108.
33. **Hansson M**, Linde A, Olsson I. Reactivation of latent Epstein Barr virus infection induces remission of splenic lymphoma with villous lymphocytes. (2005) **Int J Hematol** 81:413-6.
34. **Hansson M**, Romero A, Thoren F, Hermodsson S, Hellstrand K. Activation of cytotoxic lymphocytes by interferon-alpha: role of oxygen radical-producing mononuclear phagocytes. (2004) **J Leukoc Biol** 76:1207-13.
35. Gao Y, **Hansson M**, Calafat J, Tapper H, Olsson I. Sorting soluble tumor necrosis factor (TNF) receptor for storage and regulated secretion in hematopoietic cells. (2004) **J Leukoc Biol** 76:876-85.
36. **Hansson M**, Jonsson S, Persson AM, Calafat J, Tapper H, Olsson I. Targeting proteins to secretory lysosomes of natural killer cells as a principle for immunoregulation. (2003) **Mol Immunol** 40:363-72.
37. Mellqvist UH, **Hansson M**, Brune M, Dahlgren C, Hermodsson S, Hellstrand K. Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. (2000) **Blood** 96, 1961-8.
38. **Hansson M**, Hermodsson S, Brune M, Mellqvist UH, Naredi P, Betten A, Gehlsen KR, Hellstrand K. Histamine protects T cells and natural killer cells against oxidative stress. (1999) **J Interferon Cytokine Res** 19, 1135-44.
39. Brune M, **Hansson M**, Mellqvist UH, Hermodsson S, Hellstrand K. NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. (1996) **Eur J Haematol** 57:312-9.
40. Asea A, **Hansson M**, Czerkinsky C, Houze T, Hermodsson S, Strannegard Ö, Hellstrand K. Histaminergic regulation of interferon-gamma (IFN-gamma) production by human natural killer (NK) cells. (1996) **Clin Exp Immunol** 105:376-82.
41. **Hansson M**, Asea A, Hermodsson S, Hellstrand K. Histaminergic regulation of NK-cells: protection against monocyte-induced apoptosis. (1996) **Scand J Immunol** 44:193-6.
42. **Hansson M**, Asea A, Ersson U, Hermodsson S, Hellstrand K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. (1996) **J Immunol** 156:42-7.

II. Reviews

43. Bjorkstrand B, **Hansson M**, Blimark C, Svensson R, Nahi H, Carlson K, Izarra A, Kautto M, Turesson I, Mellqvist UH, Strandberg M, Gruber A, Lauri B (2016) Myeloma National Guidelines. Myeloma Nationella riktlinjer (<http://www.sfhem.se/riktlinjer>)
44. Ahlberg L, Andreasson J, Blimark C, Carlson K, Dahl-Hammarstedt C, Forsberg K, Garthon G, Gruber A, **Hansson M**, Hedenus M, Hedlund A, Isaksson C, Karlsson T, Kristinsson S, Lauri B, Lenhoff S, Linder O, Mellqvist UH, Mozart M, Nahi H, Rosengren S, Strandberg M, Stromberg O, Svensson R, Swedin A, Turesson I, Westin J. (2013) Myeloma, investigation and treatment. National guidelines from the Diagnosis group from plasma cell diseases (<http://www.sfhem.se/riktlinjer>)
45. **Hansson M**, Olsson I, Nauseef WM. Biosynthesis, processing, and sorting of human myeloperoxidase. (2006) **Arch Biochem Biophys** 445:214-24.

46. Olsson I, Bulow E, **Hansson M**. Biosynthesis and sorting of myeloperoxidase in hematopoietic cells. (2004) **Jpn J Infect Dis** 57, S13-4.
47. **Hansson M**, Gao Y, Rosen H, Tapper H, Olsson I. Hematopoietic secretory granules as vehicles for the local delivery of cytokines and soluble cytokine receptors at sites of inflammation. (2004) **Eur Cytokine Netw** 15:167-76.
48. Hellstrand K, **Hansson M**, Hermodsson S. Adjuvant histamine in cancer immunotherapy. (2000) **Semin Cancer Biol** 10, 29-39.
49. Hellstrand K, Brune M, Dahlgren C, **Hansson M**, Hermodsson S, Lindner P, Mellqvist UH, Naredi P. Alleviating oxidative stress in cancer immunotherapy: a role for histamine? (2000) **Med Oncol** 17:258-69.
50. Hellstrand K, Brune M, Naredi P, Mellqvist UH, **Hansson M**, Gehlsen KR, Hermodsson S. Histamine: a novel approach to cancer immunotherapy. (2000) **Cancer Invest** 18:347-55.
51. **Hansson M**. Histamine - unties the Natural Killer cells - an improvement in cancer immunotherapy? (1997) **Int Conf of PhD stud** , Medical science, Hungary, 24-30.

III. Book chapters / Thesis

52. **Hansson M**, Olsson I. Secretory lysosomes of hematopoietic cells as vehicles for therapeutically active proteins. (2005) Progress in Immunology Research (B. A. Veskler, ed) Nova Science Publishers 105-121.
53. **Hansson M**. (2000) Phagocyte-induced apoptosis in natural killer cells and T cells : role of reactive oxygen species and regulation by histamine, Göteborgs universitet.

IV. Congress abstracts

54. Kumar S, Dimopoulos M, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio E, Mateos M, O'Donnell E, Vij R, Lokhorst H, van de Donk N, Min CK, Mark T, Turesson I, **Hansson M**, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist UH, Usmani S, Dytfeld D, Badros A, Moreau P, Kim K, Rodriguez Otero P, Lee J, Shustik C, Waller D, Chang W, Ozaki S, Lee JJ, de la Rubia J, Eom H, Rosinol L, Lahuerta J, Sureda A, Kim J, Durie D. Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study (2016) Abstract 4414, Blood Abstracts: 58th Annual Meeting Abstracts Vol. 128, Issue 22.
55. Mateos MV, Masszi T, Grzasko N, **Hansson M**, Sandhu I, Pour L, Viterbo L, Jackson S, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, van de Velde H, Richardson P, Moreau P. Impact of prior therapy type on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-Rd in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1 (2016) Abstract 32662, EHA, Copenhagen DK.
56. Dimopoulos M, Grosicki S, Jedrzejczak WW, Nahi H, Gruber A, **Hansson M**, Byrne C, Labotka R, Hui AM, Teng Z, Grzasko N. Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070) (2015) Abstract 26, ASH, Orlando US.
57. Dimopoulos M, Palumbo A, Corradini P, Cavo M, Delforge M, Weisel K, Ocio EM, Di Raimondo F, **Hansson M**, Simcock M, Miller N, Slaughter A, Peluso T, Sternas L, Zaki M, Moreau P. An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (2015) Abstract 4225, ASH, Orlando US.

58. Lokhorst H, Laubach J, Nahi H, Plesner T, Gimsing P, **Hansson M**, Minnema M, Lassen U, Krejcik J, Ahmadi T, Khan I, Lisby S, Basse L, Brun N, Richardson P. Dose-dependent efficacy of Daratumumab (DARA) as monotherapy in patients with relapsed or refractory Multiple Myeloma (RR MM) (2015) ESH Nov 7-9, in Athens Greece.
59. Zweegman S, van der Holt B, Mellqvist U-H, Salomo M, Bos GMJ, Levin MD, Visser-Wisselaar H, **Hansson M**, van der Velden AWG, Deenik W, Gruber A, Coenen JLLM, Plesner T, Klein SK, Tannis BC, Sztatkowski D, Brouwer RE, Visser HPJ, Leys MBL, van de Donk NWCJ, Hauks E, van der Hem KG, Durian MF, Mattijssen EJM, Sinnige HAM, Stevens-Kroef MJPL, Sonneveld P, Waage A. Randomized phase III trial in non-transplant eligible patients with newly diagnosed symptomatic Multiple Myeloma comparing Melphalan-Prednisone-Thalidomide followed by Thalidomide maintenance (MP-Thal + Thal) versus Melphalan-Prednisone-Lenalidomide followed by Lenalidomide maintenance (MP-Len + Len). A joint study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMSG). (2014) ASH, San Francisco, US.
60. Weisel K, Dimopoulos M, Cavo M, Ocio E, Palumbo A, Corradini P, Delforge M, Oriol A, Goldschmidt H, Conticello C, Vacca A, **Hansson M**, Miller N, Peluso T, Sternas L, Zaki M, Moreau P. Pomalidomide + Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients From the Phase 3b STRATUS Trial (MM-010). (2014) ASH, San Francisco, US.
61. Palumbo A, Dimopoulos M, Weisel K, Cavo M, Ocio E, Corradini P, Delforge M, Oriol A, Goldschmidt H, Blanchard MJ, Conticello C, Vacca A, **Hansson M**, Slaughter A, Simcock M, Herring J, Peluso T, Sternas L, Zaki M, Moreau P. Outcomes for Older Patients in STRATUS (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma. (2014) ASH, San Francisco, US.
62. Lund L, Gruber A, Lauri B, Blimark C, Swedin A, **Hansson M**, Forsberg K, Ahlberg L, Carlsson C, Waage A, Gimsing P, Vangsted A, Frlund A, Hardling M, Mellqvist UH, Nahi H. The REVII Trial: Lenalidomide and Dexamethasone as Second Line Treatment in Myeloma Followed by Extended Lenalidomid vs Len/Dex. (2014) EHA, Milano, Italy.
63. Lokhorst H, Laubach J, Nahi H, Plesner T, Gimsing P, **Hansson M**, Minnema M, Lassen U, Krejcik J, Ahmadi T, Khan I, Lisby S, Basse L, Brun N, Richardson P. Dose-dependent efficacy of Daratumumab (DARA) as monotherapy in patients with relapsed or refractory Multiple Myeloma (RR MM). (2014) EHA, Milano, Italy.
64. Lokhorst H, Laubach J, Nahi H, Plesner T, Gimsing P, **Hansson M**, Minnema M, Lassen UN, Krejcik J, Ahmadi T, Lisby S, Basse L, Brun N, Richardson P. Dose-dependent efficacy of Daratumumab (DARA) as monotherapy in patients with relapsed or refractory Multiple Myeloma (RR MM). (2014) ASCO, Chicago, US.
65. Dimopoulos M, Weisel K, Cavo M, Corradini P, Delforge M, Morgan G, **Hansson M**, Palumbo A, Ocio E, Miller N, Slaughter A, Nikolova Z, Moreau P. MM-010: A Single-Arm Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) in Refractory or Relapsed and Refractory Multiple Myeloma (MM). (2014) ASCO, Chicago, US.
66. **Hansson M**, Gimsing P, Badros A, Korsgren M, Mau-Sorensen M, Nahi H, Offner F, Salomo M, Sonesson E, Van Droogenbroeck J, Zangari M, Poelman M, Tricot G. A phase I, multicenter, dose escalation study of BI-505 in relapsed/refractory multiple myeloma. (2013) International Myeloma Working Group, Kyoto, Japan.
67. Mårtensson L, **Hansson M**, Kovacek M, Frendus B, Teige I. Combined treatment with lenalidomide or bortezomib enhances in vivo antimyeloma activity of the human ICAM-1 antibody BI-505. (2013) International Myeloma Working Group, Kyoto, Japan,

68. Teige I, Mårtensson L, Lindström J, Sundberg A, Thornberg UC, Schaffer BC, Kovacek M, Ljungars A, **Hansson M**, Juliusson G, Kucci V, Ek S, Jerkeman M, Soden J, Freeth J, Mansouri L, Rosenquist R, Rader C, Cragg M, Friendus B. Comprehensive functional screening of a nave human antibody library against primary chronic lymphocytic leukaemia (CLL) cells identifies multiple antibodies and target specificities with therapeutic potential. (2013) Targeted Cancer Therapies, Keystone symposia, British Columbia, US.
69. **Hansson M**, Veitonmäki N, Fransson J, Ljungars A, Teige A and Friendus B (2011) The epitope targeted by cell death-inducing ICAM-1 antibody BI-505 is highly expressed in multiple myeloma. 3th International Myeloma Workshop, Paris, France.
70. Thorn FB, Aurelius J, Brune M, **Hansson M**, Martner A, Palmqvist L, Rowe JM, and Hellstrand K (2011) Efficacy of histamine dihydrochloride and interleukin-2 in morphologic subtypes of acute myeloid leukemia, 16th Congress of European Hematology Association, London, UK
71. Lindström J, Veitonmäki N, **Hansson, M.**, Fransson J, Ljungars A, Lindblom A, Teige A and Friendus B. (2010) A Functional Approach to Discovery of Tumor Targeting Human Antibodies. Antibody Biology and Engineering Gordon conference, Ventura CA, USA.
72. Veitonmäki N, **Hansson M**, Ljungars A, Danielsson L, Friendus B. (2009) Apoptosis-inducing ICAM-1 antibody has broad and potent anti-myeloma activity in vivo. Targeted Cancer Therapies, Keystone symposia, British Columbia, US.
73. Veitonmäki N, **Hansson M**, Ljungars A, Danielsson L, Friendus B. (2009) Apoptosis-Inducing ICAM-1 Antibody BI-505 is a potent inhibitor of Multiple myeloma. XIIth International Myeloma Workshop, Washington DC, US.
74. **Hansson M**, Nandakumar KS, Persson AM, Holmdahl R, Olsson I, (2007) Targeting of soluble tumor necrosis factor receptor to secretory lysosomes in murine hematopoietic cells in vivo. 41th Annual Scientific Meeting of the European Society for Clinical Investigation, Uppsala, Sweden.
75. Källqvist L, **Hansson M**, Persson AM, Calafat J, Tapper H, Olsson I. (2007) The tetraspanin CD63 interacts with proelastase and is required for secretory lysosome formation in granulopoietic cells. 41th Annual Scientific Meeting of the European Society for Clinical Investigation, Uppsala, Sweden.
76. Källqvist L, **Hansson M**, Persson AM, Tapper H, Olsson I. (2006) The tetraspanin CD63 interacts with neutrophil elastase and facilitates secretory lysosome targeting. Annual Meeting of the Leukocyte Biology society, San Antonio Texas, US.
77. Olsson I, **Hansson M**, Johnsson E, Källqvist L, Persson A, Tapper H. (2006) The tetraspanin CD63 interacts with neutrophil elastase and facilitates secretory lysosome targeting. 40th Annual Scientific Meeting of the European Society for Clinical Investigation, Prague, Czech Republic.
78. Källqvist L, Persson AM, **Hansson M**, Tapper H, Olsson I. (2006) Neutrophil pro-elastase sorting involves plasma membrane trafficking requiring the C-terminal propeptide. 40th Annual Scientific Meeting of the European Society for Clinical Investigation, Prague, Czech Republic.
79. **Hansson M**, Gao Y, Tapper H, Persson AM, Olsson I. (2005) Using secretory lysosomes for local delivery of cytokines or cytokine receptors. *Haematologica* 90, 479-479.
80. **Hansson M**, Calafat J, Gao Y, Persson AM, Tapper H, Olsson I. (2004) Cytokine or cytokine receptor treatment using hematopoietic secretory lysosomes as vehicles. *Blood* 104, 40B-40B.
81. Romero A, Hermodsson S, **Hansson M**, Hellstrand K. (2002) Potentiation of alpha-interferon-induced activation of NK cells and CD8+T cells by histamine dihydrochloride. *Journal Of Hepatology* 36, 155-155.
82. **Hansson M**, Romero A, Hermodsson S, Gehlsen KR, Hellstrand K. (2000) Lymphocyte apoptosis triggered by neutrophilic granulocytes. Cellular Immunity and Immunotherapy of Cancer, Keystone symposia, Santa Fe, New Mexico, January 21-27.

83. **Hansson M**, Hermodsson S, Betten A, Hellstrand K. (1999) Histamine protects T-Cells and NK-cells against oxidative stress. *Experimental Hematology* 27, 68-68.
84. **Hansson M**, Hermodsson S, Hellstrand K. (1999) Histamine protects T-cells and NK-cells against oxidative inhibition. *Proceedings of the American Association for Cancer Research Annual Meeting* 40, 78
85. **Hansson M**, Hermodsson S, Hellstrand K. (1998) Histamine protects T-cells and NK-cells against oxidative inhibition. *Blood* 92, 58B-58B.

V. Patent

86. PCT/EP2012/069132 Title of the invention: "USE OF ANTIBODIES AGAINST ICAM-1 IN THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA AND RELATED INDICATION" Applicants: BIOINVENT INTERNATIONAL AB Inventors: **Markus Hansson** and Bjorn Frendeus.
87. Publication No. WO/2012/007516 was published on 2012 January 19. Title of the invention: "USE OF ANTIBODIES AGAINST ICAM-1 IN THE TREATMENT OF PATIENTS WITH RELAPSED CANCER." Applicants: BIOINVENT INTERNATIONAL AB Inventors: **Markus Hansson** and Bjorn Frendeus.

VI. Popular scientific articles/presentations

88. Lauri L, Hveding Blimark C, Hammarstedt C, Nahi H, **Hansson M**, Mellqvist UH. (2016) Liten Myelomskola - Utbildningsmaterial - för dig som har drabbats av myelom och dina anhöriga
89. **Hansson M**, Lenhoff S. (2012) Nya behandlingar vid sjukdomen myelom (2012) *Blodcancerförbundets medlemstidning* 2012:2 6-9.
90. **Hansson M** (2012) Vad är multipelt myelom? Familjedag för anhöriga och patienter.
91. **Hansson M** (2005) Trötthet vid anemi - Blodsjukas förenings årsmöte 30 Jan.
92. **Hansson M** (2004) Fysiologi - hur kroppen fungerar. Föreläsning i kursen Att leva med cancer för anhöriga och patienter. 6 oktober.
93. **Hansson M** (2004) Diagnostik och behandling av sjukdomar i blodet Föreläsning i kursen Att leva med cancer för anhöriga och patienter. 13 oktober

VII. Submitted manuscripts

94. Lund L, Gruber A, Lauri A, Karstorp S, Duru A, Blimark C, Swedin A, **Hansson M**, Forsberg K, Ahlberg L, Carlsson C, Waage A, Gimsing P, Juul Vangsted A, Frolund U, Holmberg E, Gahrton G, Alici E, Hardling M, Mellqvist UH, Nahi H Lenalidomide versus lenalidomide + dexamethasone maintenance after second-line lenalidomide + dexamethasone in myeloma
95. Jonsson S, Sveinbjornsson G, Lopez de Lapuente A, Swaminathan B, Plomp R, Dekkers G, Ajore R, Ali M, Bentlage A, Elmr E, Eyjolfsson G, Gudjonsson S, Gullberg U, Halldorsson B, **Hansson M**, Holm H, Johansson A, Johnsson E, Ludviksson J, Oddsson A, Olafsson I, Olafsson S, Sigurdardottir O, Stefansdottir L, Masson G, Sulem P, Wuhler M, Wihlborg AK, Thorleifsson G, Gudbjartsson D, Thorsteinsdottir U, Vidarsson G, Jonsdottir I, Nilsson B, Stefansson K. Sequence variants influencing immunoglobulin levels

96. Mateos MV, Masszi T, Grzasko N, **Hansson M**, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson P, Moreau P. Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
97. Nahi H, Genell A, Wlinder G, Uttervall K, Juliusson G, Forsberg K, **Hansson M**, Svensson R, Linder O, Carlsson K, Bjrckstrand B, Kristinsson S, Mellqvist UH, Blimark C, Turesson I. A prospective population-based study on solitary plasmacytomas and plasma cells leukemia